myelofibrosis
Showing NaN - NaN of 15
Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis Trial in Worldwide (ACE-536, Placebo)
Recruiting
- Myeloproliferative Disorders
- +4 more
- ACE-536
- Placebo
-
La Jolla, California
- +184 more
Aug 22, 2022
Myelofibrosis Trial in Worldwide (Imetelstat, Best Available Therapy (BAT))
Recruiting
- Myelofibrosis
- Imetelstat
- Best Available Therapy (BAT)
-
La Jolla, California
- +165 more
Aug 19, 2022
Myelofibrosis Trial in Worldwide (Ruxolitinib, Siremadlin, Crizanlizumab)
Suspended
- Myelofibrosis
- Ruxolitinib
- +5 more
-
Adelaide, South Australia, Australia
- +37 more
Aug 18, 2022
Myelofibrosis Trial in Worldwide (Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg)
Completed
- Myelofibrosis
- Imetelstat 4.7 mg/kg
- Imetelstat 9.4 mg/kg
-
Birmingham, Alabama
- +71 more
Aug 17, 2021
Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)
Completed
- Polycythemia Vera
- +2 more
- JAK2V617F mutation
-
Olomouc, Czechia
- +29 more
Dec 5, 2019
Myelofibrosis Trial in Worldwide (Ruxolitinib, Best Available Therapy (BAT))
Completed
- Myelofibrosis
- Ruxolitinib
- Best Available Therapy (BAT)
-
Innsbruck, Austria
- +60 more
Jul 11, 2019
Patients With Myeloproliferative Disorders
Completed
- Myeloproliferative Disease
- +4 more
-
Scottsdale, Arizona
- +21 more
Dec 12, 2018